^
    Back
    Association details:
    Biomarker:HR positive + MYC mutation
    Cancer:HER2 Negative Breast Cancer
    Drug Class:CDK4 inhibitor +
    CDK6 inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO 2022
    Title:

    Identifying genetic factors of response and resistance to CDK4/6 inhibitors in metastatic HR+/HER2-breast cancer using real-world data.

    Published date:
    05/26/2022
    Excerpt:
    ...HR+/HER2- MBC patients with age > 18 years treated with at least one of the CDK4/6 inhibitors….In addition, amplifications and gain of function mutations in MYC and associated genes were also significantly enriched in the non-responder population (Z value = 2.71; P value = 0.01; N = 44).
    DOI:
    10.1200/JCO.2022.40.16_suppl.1064